SEARCH RESULTS FOR:
R&D: Is Innovation Really Happening in China?
With an ever-increasing stockpile of innovative technologies and a growing network of talented scientists intently focused on innovation, it will merely be a matter of time before China begins to produce some of the most cutting-edge drugs.
Manpower Constraints a Persistent Burden for Industry in Singapore
Singapore Chemicals 2018
As the city-state continues its relentless pursuit towards an ecosystem of utopian standards, Industry 4.0 will take it on a new course. This evolution will demand economic, social, and educational change.
Gary Chan
MANAGING DIRECTOR ASIA PACIFIC, BDP INTERNATIONAL
Singapore Chemicals 2018
BDP in Singapore explains to GBR how it is levering technology to improve service.
Jason Goh
CEO ASIA, YANG KEE LOGISTICS
Singapore Chemicals 2018
Yang Kee Logistics is currently the largest homegrown logistics provider in Singapore, and has grown rapidly to a regional player with global ambitions.
Gan Seow Kee
MANAGING DIRECTOR, EXXONMOBIL ASIA PACIFIC PTE LTD.
Singapore Chemicals 2018
Singapore is home to ExxonMobil’s largest integrated refining and petrochemical complex, which has a crude oil processing capacity of 592,000 barrels per day.
John Kanyoni
COO DRC, TEMBO POWER
Tembo Power explains its plans to develop hydropower in the DRC that will supply the growing demand from the countries mines.
Richard Young
PRESIDENT & CEO, TERANGA GOLD
With a producing gold mine in Senegal, Teranga’s exploration focus for 2018 is on Burkina Faso and Cote d’Ivoire.
Vehip Kaci & Ulrich Ruppel
GENERAL MANAGER & DEPUTY GENERAL MANAGER, DMT TURKEY BRANCH
Turkey Mining 2018
GBR speaks to DMT about its operations in Turkey.
Mbiya Ngandu
DIRECTOR, TRUST MERCHANT BANK (TMB)
GBR talks to TMB, a leading corporate and commercial bank in DRC, about what is attracting investments to the country and the services that the bank can offer.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
